Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04811846 | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | active not recruiting | N/A | 40 | University Teaching Hospital Hall in TirolOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 |
| clinicaltrials |
| NCT06723496 | Psychiatric Problems in Children With Acute Lymphoblastic Leukemia and Their Caregivers | active not recruiting | — | 90 | Assiut UniversityOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02221778 | SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE | active not recruiting | Phase 2 | 25 | University of Sao PauloOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02315716 | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma(Cardamon) | active not recruiting | Phase 2 | 281 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04565769 | Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Aarhus University HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | active not recruiting | — | 2,001 | Yuhan CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02406222 | Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)(MUKseven) | active not recruiting | Phase 2 | 124 | University of LeedsOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06717464 | Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer | active not recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Mupet) | active not recruiting | — | 150 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03869034 | HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC(HAICPD1-HCC) | active not recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT03356262 | The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort(QUALITY) | active not recruiting | — | 630 | St. Justine's HospitalOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT03395587 | Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma(GlioVax) | active not recruiting | Phase 2 | 136 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | active not recruiting | Phase 3 | 976 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Nov 29, 2024 | clinicaltrials |
| NCT03671018 | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 422 | Hoffmann-La RocheINDUSTRY | 5 | Nov 29, 2024 | clinicaltrials |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02385214 | MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma(MelMarT) | active not recruiting | N/A | 400 | Melanoma and Skin Cancer Trials LimitedOTHER | 5 | Nov 27, 2024 | clinicaltrials |
| NCT03449953 | Critical Care Outcomes of Hematologic Oncology Patients(COHO) | active not recruiting | — | 415 | Mount Sinai Hospital, CanadaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05396157 | Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study | active not recruiting | — | 813 | Mount Sinai Hospital, CanadaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04147533 | Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia(HALF) | active not recruiting | Phase 2 | 150 | Masaryk UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02167490 | Sentinel Node Vs Observation After Axillary Ultra-souND(SOUND) | active not recruiting | N/A | 1,560 | European Institute of OncologyOTHER | 4 | Nov 25, 2024 | clinicaltrials |
| NCT04923906 | Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | active not recruiting | Phase 3 | 624 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | active not recruiting | Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | active not recruiting | Phase 2 | 32 | Wei ZhouOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06239532 | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 2 | 28 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699316 | Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall)(ProCoPall) | active not recruiting | N/A | 160 | Erasmus Medical CenterOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699524 | Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid | active not recruiting | — | 122 | Shen FengOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03155191 | Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia(TBI-1501) | active not recruiting | Phase 1 / Phase 2 | 21 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04423731 | Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) | active not recruiting | — | 251 | Oslo University HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04868396 | Patient-derived Glioma Stem Cell Organoids | active not recruiting | — | 60 | Maastricht Radiation OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | active not recruiting | Phase 1 / Phase 2 | 23 | Joshua BrodyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT04294264 | TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer | active not recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02653118 | Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) | active not recruiting | — | 4,453 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03024684 | Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment(SHOT) | active not recruiting | Phase 4 | 240 | Chiayi Christian HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03813836 | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC(POPPY) | active not recruiting | Phase 2 | 63 | University College, LondonOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT06642506 | Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma | active not recruiting | — | 20 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2024source: clinicaltrials